Skip to main content
. 2006 Oct 3;95(9):1212–1219. doi: 10.1038/sj.bjc.6603367

Figure 3.

Figure 3

Antitumour effect following systemic administration of NTR-recombinant C. sporogenes spores to nu/nu mice bearing HCT116 tumours. (A) Tumour growth after one cycle of recombinant C. sporogenes treatment with CB1954 prodrug (▪) or vehicle only (sham) (▴) treatment. Control animals received no treatment (•) or CB1954 alone (▾). (B) Representative body weight evolution during a treatment cycle. Data are from at least five mice per group with error bars showing standard deviations for each group. Tumour volumes are normalised to 100 arbitrary units at the start of the treatment, allowing comparison of tumour growth within and across groups.